奥曲肽长效生物可降解微球的制备工艺研究

运用复乳法制备奥曲肽PLGA长效生物可降解微球,并用正交法优化微球制备工艺。利用HPLC、显微镜、激光粒度仪等对微球进行综合质量研究。结果表明,复乳法制备奥曲肽微球的最佳工艺参数为:内水相药物与中油相PLGA的质量比为1∶5,中油相PLGA的浓度为10%,外水相乳化剂为1%的22 000分子量聚乙烯(PVA)水溶液,中油相与外水相的体积比不小于1∶50,复乳化采用机械搅拌法,搅拌速度为1 200 r/min。在该工艺条件下制得的微球,包封率为35.1%,载药量为2.98%,平均粒径为26.3μm,微球外观圆整,形态良好。     

明胶微球载药及其体外释放性能研究

以阿司匹林为药物模型分子,制备了载阿司匹林明胶微球。SEM研究表明,明胶微球在载药后,表面结构变得更为紧实。载药性能探讨表明,当阿司匹林的投药量为16mg时,明胶微球的载药性能较优（载药量为7．3％,包封率为57．5％）。对明胶微球在人工体液中的释药性能研究显示,载阿司匹林明胶微球具有良好的缓释性能。由于具有较大的酸性和胃蛋白酶的存在,微球在人工胃液中药物释放效率较高,在人工胃液和人工肠液中药物的释放率分别为40％和28％,且一级动力学模型对微球的体外药物释放情况拟合度较高。     

石杉碱甲水凝胶微球的制备及体外释放评价

以羟丙基甲基纤维素为原料,二乙烯基砜为交联剂,采用反相悬浮聚合法制备水凝胶微球。采用透射电子显微镜、纳米粒度仪对微球的粒径、形态进行表征。采用超滤离心法收集载药微球,透析袋法考察体外释放度。研究表明,制备的水凝胶微球粒径分布均匀,分散性好,载药量达到3. 8%以上。石杉碱甲水凝胶微球能够缓释石杉碱甲约400 min,所制备的水凝胶微球对石杉碱甲具有一定的缓释作用。     

环孢素A海藻酸盐缓释微球的制备及体外释放

针对角膜移植术后免疫排斥治疗研究背景,以多肽类免疫抑制剂环孢素A为药物模型,以海藻酸钠为载体材料,以辛癸酸甘油酯和Tween20为添加剂,采用脉冲电场工艺制备药物控释微球载体,对制备工艺参数进行正交设计优化。载药微球最佳制备处方为海藻酸钠质量分数0.8%、油水体积比1∶1.5、Tween20质量分数6.5%、环孢素A投药量65 mg。载药微球球型度优良,平均粒径(36.344±0.103)μm,粒径分布跨距2.314,药物包封率(86.03±0.65)%。在符合漏槽条件的人工泪液中,7 d累积释放率为56.5%,既能满足手术局部对药物浓度需求,又具有良好缓释性能。     

尼莫地平PLGA微球的制备方法改良及其特性研究

用乳化 溶剂挥发法制备尼莫地平（nimodipine,NMP）PLGA微球,在油相中引入石油醚与二氯甲烷作混合溶剂,考察了石油醚对微球性质的影响。石油醚与二氯甲烷的不同体积比（0,1∶10,1∶8,1∶4和1∶2）可调节微球的固化速率,从而得到不同特性的载药微球。混合比为1∶10时,微球突释效应减轻,包封率显著提高。以PLGA浓度、投药比及混合溶剂比为考察因素进行了正交优化设计。结果表明优化后微球包封率提高52.2%,突释率降低58.8%,药物以无定形态存在于微球中,与单一溶剂组相比,微球形态有较大改善,微球缓释效应显著增强。     

生物可降解聚合物纳米微囊微球的制备与应用

对生物可降解聚合物纳米微囊微球的特点、分类、选材、制备、释放机理、应用等各方面进行了系统的阐述。     

羧甲基壳聚糖离子配位微球的制备及性能研究

以羧甲基壳聚糖(CMCHS)为主要原料,采用静电脉冲液滴发生器制备羧甲基壳聚糖离子配位微球。光学显微镜观察微球具备规整形貌,扫描电镜分析显示干球粒径约为100μm且表面呈多孔结构;红外光谱证明其内部具有由CMCHS上的羧酸根与Ca^2 配位形成的羧酸盐结构。溶胀实验表明,CMCHS溶液浓度、金属离子种类及其浓度等制备条件均影响微球的溶胀性能．且其溶胀行为对pH值较敏感。药物体外释放初步研究表明,CaCl2浓度和释放介质pH值均对微球的释放性能产生影响。研究对其进一步应用于药物释放等领域具有重要意义。     

阿司匹林载药淀粉微球吸附性能的研究

以可溶性淀粉为原料,研究了淀粉微球在反相悬浮体系中对阿司匹林的吸附作用。探讨了交联剂用量、引发剂用量、反应时间及搅拌速度对微球药物吸附量的影响,并考察其体外释放情况。结果表明：当交联剂用量为12g/L,引发剂用量为3g/L时,60℃下中速搅拌2.0h,淀粉微球对阿司匹林有较大吸附作用。在酸性条件下,阿司匹林淀粉微球在8h内有较好释放,交联剂用量对释药速率有较大影响。     

卵清蛋白-PLGA抗原微球脉冲释放系统的研究

目的：以OVA为模型抗原研制具有脉冲释放特性的OVA-PLGA微球并对其在小鼠体内的免疫效果进行评价。方法：复乳法研制OVA-PLGA微球;光学显微镜和电子显微镜法研究微球的形态、粒径和粒径分布;Bradford法测定微球的载药量和包封率;微量溶出度测定法研究微球的体外释放规律;按注射剂的要求研制含OVA-PLGA微球...     

Comparison of release behaviour from microcapsules and microspheres

The plasticizing effect of core oil in the polymer shell of core–shell particles, so-called microcapsules, was here examined. The study involved release measurements of 4-nitroanisole into aqueous solution from two types of microparticles. In the first study, a microcapsule with PMMA shell and hexadecane core was examined. The second type of particle was a homogeneous PMMA microsphere containing no oil. Experimental data were compared to models that describe release by a diffusion mechanism out from core–shell particles as well as homogeneous spherical particles. Results clearly show that the alkane oil has a plasticizing effect on the PMMA shell, thereby generating a faster release of 4-nitroanisole. In both types of microparticles, the diffusion coefficients of 4-nitroanisole could be determined. The findings increase our understanding of important parameters in the microcapsule design with regard to tuning the release behaviour. Using microparticles, the ambition is to prolong the protection of paint and other coatings against fouling.     

pH响应性的虾青素壳聚糖微球制备及应用

以氯乙酸和壳聚糖为原料，通过N,O-羧甲基化化学改性方法制备了水溶性羧甲基壳聚糖，并以此为原料通过乳液法制备羧甲基壳聚糖微球和羧甲基壳聚糖负载虾青素微球。考察了羧甲基壳聚糖微球的形态、分散性和粒径。结果表明，微球最佳制备条件为：羧甲基壳聚糖含量（以水相即去离子水质量为基准，下同）1.0%，油水体积比1∶1，表面活性剂Span 80含量（以油相即液体石蜡体积为基准，下同）4.0%，交联剂戊二醛含量（以油相即液体石蜡体积为基准，下同）7.5%，剪切速率4000 r/min。红外测试表明，微球成功负载虾青素，在虾青素初始添加量为20mg的载药率和包封率分别为10.74%和67.24%。在模拟胃液和模拟肠液中，负载虾青素微球的释放率分别为10%和85%。羧甲基壳聚糖可以用作药物载体。     

In vitro release of complexed pDNA from biodegradable polymer films

The controlled delivery of low‐molecular weight drugs and proteins from biodegradable polymers has received considerable attention. However, controlled release studies of pDNA from such polymers have not been reported to date. In this study, a plasmid DNA was complexed with the cationic polymer called polyethylenimine (PEI). This gene vector has been shown to be very effective in transfecting cells. The complexed DNA were then incorporated into different types of poly‐lactic‐co‐glycolic acid (PLGA) film; PLGA 53/47 (M_w 90 kDa), 50/50 (M_w 11 kDa, end group is lauryl ester) and 75/25 (M_w 120 kDa). Their release profiles from a buffer solution were studied. An initial (small) burst release of PEI‐DNA from film was observed in PLGA 53/47 and 50/50, followed by a plateau phase and finally a rapid erosion‐controlled release. For PLGA 50/50, the rapid release started after 14 days; erosion‐controlled release for PLGA 53/47 started after 9 days; for PLGA 75/25, the release rate was governed by an initial burst release (10%) followed by a slow release controlled by diffusion. No obvious erosion‐controlled release rate was observed for this polymer up to 27 days. Thus, the controlled release of complexed DNA follows the general features exhibited by lower‐ M_w drugs. This is of significance in designing gene vector matrices that offer the promise of more lasting gene therapy compared with particulate formulations. © 2008 Wiley Periodicals, Inc. J Appl Polym Sci, 2008     

可降解聚乳酸多孔微球的制备探究

以聚乳酸为壁材,碳酸氢铵为致孔剂,采用双乳液溶剂挥发法,制备出具有孔状的聚乳酸微球,探讨制备条件对聚乳酸微球的影响.结果表明,在内外水相体积比1∶7.5,初乳化搅拌速度1 000 r/min下制得的PLA多孔微球的球形和孔结构较好.     

Sustained release of IL-1Ra from biodegradable microspheres prolongs its IL-1-neutralizing effects

A sustained delivery system for interleukin-1 receptor antagonist (IL-1Ra) may have great therapeutic and industrial potential due to the cytokine activity as an IL-1 inhibitor. Here, we investigated the capability of biodegradable polymeric microspheres to sustain the release and prolong the therapeutic efficacy of IL-1Ra. IL-1Ra was encapsulated within rapidly degrading poly(lactic/glycolic acid) PLGA RG502H microspheres, which showed a desirable release profile of IL-1Ra in vitro. Pharmacokinetic study in mice revealed elevated serum levels of the recombinant IL-1Ra (rIL-1Ra) for up to 8 days following subcutaneous injection of IL-1Ra microspheres. In comparison, the serum levels of rIL-1Ra following subcutaneous or intravenous bolus injection of the soluble cytokine decreased very rapidly; within 48 h no recombinant cytokine was detected in mice sera. The sustained delivery of rIL-1Ra for over two weeks was efficient in inhibiting IL-1ß-stimulated induction of serum IL-6. These results suggest that the present therapeutic protocol of daily bolus injections of the IL-1Ra may be replaced by a weekly injection of IL-1Ra within PLGA RG502H microspheres.     

Investigation on preparation and protein release of biodegradable polymer microspheres as drug‐delivery system

Among the different approaches to achieve protein delivery, the use of polymers, especially biodegraded, holds great promise. This work aimed to study the preparation and protein release of a novel drug‐delivery system based on human serum albumin (HSA) encapsulated into biodegradable polymer microspheres. The microspheres containing HSA were elaborated by the solvent‐extraction method based on the formation of multiple w/o/w emulsion. The encapsulation efficiency (E.E.) of HSA was determined by the CBB method. Alginate/alginate and calcium chloride was added into an internal aqueous phase to investigate the protein loading efficiency, protein stability, and in vitro release profiles. Microspheres were characterized in terms of their morphology, size distribution, loading efficiency, and in vitro protein release. SDS–PAGE results showed that HSA kept its structural integrity during the encapsulation and release procedure. In vitro studies indicated that the microspheres with alginate added in the internal aqueous phase had a smaller extent of burst release. In conclusion, the work presents a new approach for macromolecular drugs (such as protein drugs, vaccines, and peptide drugs) delivery. © 2002 John Wiley & Sons, Inc. J Appl Polym Sci 84: 778–784, 2002; DOI 10.1002/app.10327     

载阿霉素聚乳酸多孔微球的表征及释药性能

以阿霉素（DOX）为小分子化学药物模型,采用吸附法对聚乳酸（poly-L-lactide,PLLA）多孔微球进行载药,采用场发射扫描电子显微镜（FE-SEM）、傅里叶变换红外光谱（FTIR）、X射线衍射（XRPD）及差示扫描量热（DSC）对DOX-PLLA复合微球的形貌粒径及空气动力学性能、药物及材料的理化性能、载药性能进行表征,并且研究了其载药量、包封率和体外释放性能。结果表明,不同载药量之间的PLLA多孔微球粒径并无显著差异,均具有良好的空气动力学性能,适合肺部可吸入给药的条件;化学组成未见明显改变,物理结构由结晶态变为无定形态;随载药量的增加（2.9%,4.0%,4.6%）,包封率逐渐降低（56%,51%,44%）;药物的体外释放与原料药相比具有一定的缓释效果,最长释放时间可达5天,表明DOX-PLLA复合微球有望作为缓释制剂用于肺部给药。